Why the study?
Does aspirin reduce inflammation (CRP and IL-6) in patients with type 2 diabetes without cardiovascular disease?
Population
40 patients with type 2 diabetes without cardiovascular disease
Comparison
Aspirin 100 mg or 300 mg for 6 weeks vs Placebo for 6 weeks
Design
RCT, randomized, double-blind
Follow-up
6 weeks per period
Key result
A 6-week course of aspirin did not significantly reduce CRP (mean reduction 1.23 vs 0.04 mg/l increase; P=0.366) or IL-6 compared to placebo in type 2 diabetes without cardiovascular disease.
Authors
Loading...
No anti-inflammatory effect of aspirin in T2D without CVD; leaves open longer-term or broader population effects.
RCT (n=40)
Double-blind
randomized
Does aspirin reduce inflammation (CRP and IL-6) in patients with type 2 diabetes without cardiovascular disease?
p-value: p=0.366
A 6-week course of aspirin (100 mg or 300 mg) does not significantly reduce inflammatory markers (CRP and IL-6) in patients with type 2 diabetes without cardiovascular disease.
Hovens et al. (2007) conducted an RCT in Type 2 diabetes without cardiovascular disease (n=40). Aspirin vs. Placebo was evaluated on Plasma C-reactive protein (CRP) and interleukin-6 (IL-6) levels (p=0.366). A 6-week course of aspirin did not significantly reduce CRP (mean reduction 1.23 vs 0.04 mg/l increase; P=0.366) or IL-6 compared to placebo in type 2 diabetes without cardiovascular disease.